» Articles » PMID: 23541470

Nutritional Protective Mechanisms Against Gut Inflammation

Overview
Journal J Nutr Biochem
Date 2013 Apr 2
PMID 23541470
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory bowel disease (IBD) is a debilitating and widespread immune-mediated illness characterized by excessive inflammatory and effector mucosal responses leading to tissue destruction at the gastrointestinal tract. Interactions among the immune system, the commensal microbiota and the host genotype are thought to underlie the pathogenesis of IBD. However, the precise etiology of IBD remains unknown. Diet-induced changes in the composition of the gut microbiome can modulate the induction of regulatory versus effector immune responses at the gut mucosa and improve health outcomes. Therefore, manipulation of gut microbiota composition and the local production of microbial-derived metabolites by using prebiotics, probiotics and dietary fibers is being explored as a promising avenue of prophylactic and therapeutic intervention against gut inflammation. Prebiotics and fiber carbohydrates are fermented by resident microflora into short chain fatty acids (SCFAs) in the colon. SCFAs then activate peroxisome proliferator-activated receptor (PPAR)γ, a nuclear transcription factor with widely demonstrated anti-inflammatory efficacy in experimental IBD. The activation of PPARγ by naturally ocurring compounds such as conjugated linoleic acid, pomegranate seed oil-derived punicic acid, eleostearic acid and abscisic acid has been explored as nutritional interventions that suppress colitis by directly modulating the host immune response. The aim of this review is to summarize the status of innovative nutritional interventions against gastrointestinal inflammation, their proposed mechanisms of action, preclinical and clinical efficacy as well as bioinformatics and computational modeling approaches that accelerate discovery in nutritional and mucosal immunology research.

Citing Articles

Network pharmacology integrated with molecular docking and molecular dynamics simulations to explore the mechanism of Shaoyao Gancao Tang in the treatment of asthma and irritable bowel syndrome.

Ren M, Ma J, Qu M Medicine (Baltimore). 2024; 103(50):e40929.

PMID: 39686413 PMC: 11651441. DOI: 10.1097/MD.0000000000040929.


Microencapsulation and characterization of pomegranate seed oil using gum Arabic and maltodextrin blends for functional food applications.

Mangope K, Kaseke T, Fawole O Food Sci Nutr. 2024; 12(11):9252-9267.

PMID: 39620037 PMC: 11606825. DOI: 10.1002/fsn3.4493.


Brain Short-Chain Fatty Acids Induce ACSS2 to Ameliorate Depressive-Like Behavior via PPARγ-TPH2 Axis.

Chen N, Xu X, Guo Y, Zhao M, Li Y, Zhou T Research (Wash D C). 2024; 7:0400.

PMID: 38939042 PMC: 11210491. DOI: 10.34133/research.0400.


Gut microbiota profile in CDKL5 deficiency disorder patients.

Borghi E, Xynomilakis O, Ottaviano E, Ceccarani C, Vigano I, Tognini P Sci Rep. 2024; 14(1):7376.

PMID: 38548767 PMC: 10978852. DOI: 10.1038/s41598-024-56989-0.


A chemically-defined growth medium to support Lactobacillus-Acetobacter sp. community analysis.

Aumiller K, Scheffler R, Stevens E, Guvener Z, Tung E, Grimaldo A PLoS One. 2023; 18(10):e0292585.

PMID: 37824485 PMC: 10569604. DOI: 10.1371/journal.pone.0292585.


References
1.
Fuss I, Boirivant M, Lacy B, Strober W . The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol. 2002; 168(2):900-8. DOI: 10.4049/jimmunol.168.2.900. View

2.
Mao Y, Nobaek S, Kasravi B, Adawi D, Stenram U, Molin G . The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats. Gastroenterology. 1996; 111(2):334-44. DOI: 10.1053/gast.1996.v111.pm8690198. View

3.
Shanahan F . Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005; 288(3):G417-21. DOI: 10.1152/ajpgi.00421.2004. View

4.
Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

5.
Stuber E, Strober W, Neurath M . Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med. 1996; 183(2):693-8. PMC: 2192468. DOI: 10.1084/jem.183.2.693. View